Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies

Lung Cancer（2023）

引用 0|浏览10

暂无评分

摘要

•Rezivertinib showed favorable efficacy for NSCLC patients with EGFR T790M+ and CNS metastases.•Among 150 patients of cFAS, the median CNS-DoR was 13.8 (95% CI: 9.6-not calculable [NC]) months.•The median CNS-PFS was 16.5 (95%CI: 13.7-NC) months in cFAS.•The safety profile was favorable.

查看译文

关键词

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要